In comparison to conventional cytotoxic chemotherapy, epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) provide significantly improved objective response rates and progression-free survival (PFS) for patients with advanced cases of NSCLC with EGFR mutations [4–6]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.